Vifor Pharma

• In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen
• In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933 (later to be renamed Vifor Pharma Ltd. in 2017)
• In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines
• In 1983, Hausmann AG laboratories is acquired by Galenica
• In 1991, Vifor (International) Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products
• In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation,[2] Vifor Ltd. and Vifor (international) Ltd. are integrated in Vifor Pharma.
• In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company
• In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
• In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé
• In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion[3]
• In 2017, the IPO of Galenica Santé (GALE) is completed and listed on the Swiss Stock Exchange. Galenica AG (GALE) and Vifor Pharma AG (VIFN) are listed as independent entities since
• In 2019, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) received the Swiss Success Award from the non-profit organisation Swiss Biotech Association[4]
• In 2020, Vifor Pharma sells 100% of OM Pharma to Optimus Holding Limited for CHF 435 million[5]
• In November 2021, Vifor Pharma Group acquired Sanifit with its novel inhibitor of vascular calcification SNF472 for the treatment of calcific uremic arteriolopathy (CUA) and peripheral artery disease (PAD) in patients with end-stage kidney disease. On the same day, Vifor announced the acquisition of Swiss-based Inositec who develops treatments for soft tissue and vascular calcification disorders and aortic valve stenosis (AVS).[6]
• In December 2021 CSL Limited announced it would acquire Vifor Pharma for CHF 10.9 billion (US$11.7 billion).[7] The capital raising is considered one of the ten largest secondary-market deals worldwide in 2021.[8]

Vifor Pharma is active in the treatment of iron deficiency and iron deficiency anaemia.[9] The Group also has a focus on the management of conditions in nephrology, cardiology and rare diseases. Iron deficiency treatments Ferinject and Injectafer were accountable for more than a third of its revenues in 2021.[1]

In 2017, Vifor Pharma Group was listed (ticker symbol VIFN) on the Swiss Stock Exchange (SIX) after splitting up the former Galenica Group. This was completed through an initial public offering (IPO) of Galenica Santé (listed as GALE).

Vifor Pharma Group is a member of a number of trade associations that advocate on behalf of the pharmaceutical industry and for the policy positions commonly shared, this includes the European Federation of Pharmaceutical Industries and Associations (EFPIA).[10]

Vifor Pharma Group is present in North and South America, Europe, the Middle East and Asia Pacific and works with over 100 partners all around the world.

Vifor Pharma Group develops, manufactures and markets pharmaceutical products including prescription and non-prescription products. The Group's businesses include Vifor Pharma, focused on iron deficiency and iron deficiency anaemia, and Vifor Fresenius Medical Care Renal Pharma, focused on kidney disease patients, including anaemia, mineral and bone management, cardio-renal conditions, and rare diseases.

Across the Group there are manufacturing and R&D sites in Switzerland and Portugal. Raw materials are sourced globally with active pharmaceutical ingredients manufactured in Switzerland, Germany and Austria. Final products are manufactured by partners across Europe, Turkey and North America.

• Official website